Abstract
Many different approaches have been evaluated to prevent restenosis in stents after vascular implantation. Currently, drug-eluting stents are extremely promising in suppressing neointimal hyperplasia. Various animal studies and randomized trials in humans have shown excellent results in terms of safety and efficacy during intermediate-term follow-up. This article will give an overview of experimental and clinical data of the different agents in published and ongoing trials.
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage
-
Anti-Inflammatory Agents / administration & dosage
-
Arterial Occlusive Diseases / prevention & control*
-
Coronary Restenosis / prevention & control*
-
Dexamethasone / administration & dosage
-
Drug Delivery Systems
-
Humans
-
Immunosuppressive Agents / administration & dosage
-
Paclitaxel / administration & dosage
-
Prosthesis Design
-
Recurrence
-
Sirolimus / administration & dosage
-
Stents*
-
Vascular Patency*
Substances
-
Angiogenesis Inhibitors
-
Anti-Inflammatory Agents
-
Immunosuppressive Agents
-
Dexamethasone
-
Paclitaxel
-
Sirolimus